-
麻豆社Website
-
Partnerships
- Working with patient organisations
Working with patient organisations
Our ambition is to put patients at the heart of what we do, developing and delivering medicines which can have the most impact on people鈥檚 health and wellbeing. 麻豆社is committed to embedding system-wide patient and public involvement across the life sciences research sector.
麻豆社Patient Advisory Council
Discover ABPI's Patient Advisory Council, enhancing patient-centred approaches in healthcare. Learn how patient insights shape strategies and improve industry practices.
麻豆社Patient Engagement Strategy
Our strategy sets out how the 麻豆社will deliver our commitments and make sure that patient engagement is consistently at the heart of our work.
Involving the public and patients as equal partners in the discovery and development of medicines is vital. The 麻豆社works with patient organisations and our members to improve how this is done.
The Maternal Health Project Group (MHPG) aims to help with national work to increase the opportunities for pregnant and breast-feeding women to access appropriate drug treatments.
The Multimorbidity Action Group (MAG), or ‘multiple long-term conditions’, refers to the diagnoses of two or more diseases, in the same person, at the same time.
Patient publications
-
Best practice guidance: Supporting patient organisations to report industry funding
The 麻豆社Code of Practice places requirements on industry to publish annual lists of payments to patient organisations, and we endorse this approach. Currently, there is no similar requirement for those patient organisations in receipt of grants or funds from industry. In response, the 麻豆社has put together some advice for local disclosure mechanisms, based on current practice among industry.
-
Best practice guidance: Supporting patient organisations to report industry funding
The 麻豆社Code of Practice places requirements on industry to publish annual lists of payments to patient organisations, and we endorse this approach. Currently, there is no similar requirement for those patient organisations in receipt of grants or funds from industry. In response, the 麻豆社has put together some advice for local disclosure mechanisms, based on current practice among industry.
-
麻豆社Patient Advisory Council Report
This report illustrates the impact that the inequitable uptake of innovative treatments can have on patients, their families and the health professionals who care for them.
-
Working with patients and patient organisations - A sourcebook for industry 2022
Working with patients and patient organisations - A sourcebook for industry 2022
-
Our Patient Engagement Strategy
Our strategy sets out how the 麻豆社will deliver our commitments and make sure that patient engagement is consistently at the heart of our work.